ACR Convergence - American College of Rheumatology Convergence

FDA officials discuss safety data and drug approvals at the American College of Rheumatology Annual Meeting.

A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.

With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.

Patients with osteoarthritis may be able to receive targeted therapy based on phenotypes.

Major adverse cardiovascular event rates for baricitinib stabilize over time.

Methotrexate discontinuation was not observed to impact rheumatoid arthritis treatment with tocilizumab, according to an abstract presented at the 2017 American College of Rheumatology Annual Meeting.

Some patients with rheumatoid arthritis require a refined treat-to-target plan.

Low incidence of 14-3-3η in patients with long-term RA, chronic HCV with arthralgias.

Treatment for psoriatic arthritis may impact symptoms and patient-reported outcomes.

Flares and immune-related adverse events are common among patients with rheumatologic diseases but can often be successfully managed.

Study finds improved mental health resources and non-pharmacologic treatment options may be effective in reducing reduce opioid exposure among children with juvenile fibromyalgia syndrome.

Patients with active psoriatic arthritis experience significant work instability based on disease activity.

Study finds high unmet need among patients with uncontrolled gout.

Biomarker identification may improve abatacept (Orencia) treatment for rheumatoid arthritis.

Patients with rheumatoid arthritis who switched to biologics or triple therapy had a longer time to treatment failure versus augmented oral methotrexate.

Several modalities found to be effective in the triage of psoriasis patients with musculoskeletal symptoms, according to a study presented at the 2017 American College of Rheumatology meeting.

Current treatment options for dermatomyositis may be ineffective for some patients, according to a study presented at the American College of Rheumatology Annual Meeting.

Medivir to present positive data at the annual meeting of the American College of Rheumatology.

Baricitinib significantly improved patient-reported outcomes in individuals with RA.

New drugs for psoriatic arthritis discussed during a session at the ACR/ARHP conference.

At the Annual Meeting of the American College of Rheumatology in Washington, DC, several experts presented their progress in harnessing technology to help teenagers and young adults manage their juvenile arthritis.

Study compares the safety and efficacy of sarilumab with adalimumab in patients who cannot tolerate methotrexate.

An ACR session focused on the Sunshine Act and health care transparency.

Sarilumab shows promise on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate.

Patients with rheumatoid arthritis who demonstrate a less-than-adequate response to a tumor necrosis factor inhibitor can be treated with another disease-modifying antirheumatic drug.

Regulatory perspectives presented at ACR on biosimilars entering the market convey the importance of crafting antibodies to our own purposes.

New guidelines for rheumatoid arthritis treatment discussed at ACR conference.

ACR session reinforces the need for new research about how the genome, epigenome, and other factors play a role in rheumatoid arthritis.

There is building consensus that multiple sclerosis and rheumatoid arthritis display similar autoimmune genetic pathways.

Clinicians who marry technical skills with humanities can see their patients and themselves in the larger context of family, society, history, politics, and economics.